Figures & data
![](/cms/asset/cbe39bdc-d61f-460a-9696-45da12474fee/dcop_a_12164074_uf0001_b.jpg)
Table 1 Comparisons of Characteristics Between Pioglitazone Never Users and Ever Users
Figure 1 The step-by-step procedures applied in the enrollment of propensity score-matched pairs of ever users and never users of pioglitazone.
![Figure 1 The step-by-step procedures applied in the enrollment of propensity score-matched pairs of ever users and never users of pioglitazone.](/cms/asset/faba65dd-4b80-404b-864e-a706860d6761/dcop_a_12164074_f0001_b.jpg)
Figure 2 The Kaplan–Meier curves for COPD-free probability with regards to pioglitazone exposure. (A) compares pioglitazone ever users to never users (logrank test, P = 0.0014). (B) compares tertiles of cumulative duration of pioglitazone therapy to never users (logrank test, P = 0.0039).
![Figure 2 The Kaplan–Meier curves for COPD-free probability with regards to pioglitazone exposure. (A) compares pioglitazone ever users to never users (logrank test, P = 0.0014). (B) compares tertiles of cumulative duration of pioglitazone therapy to never users (logrank test, P = 0.0039).](/cms/asset/3a7a3fa9-d1b5-433a-aeff-7e5fe03d74d8/dcop_a_12164074_f0002_c.jpg)
Table 2 Incidence Rates of Chronic Obstructive Pulmonary Disease and Hazard Ratios by Pioglitazone Exposure
Table 3 Joint Effects Between Pioglitazone and Risk Factors of Chronic Obstructive Pulmonary Disease